Key result
Direct oral anticoagulants effectively prevent thromboembolic events in atrial fibrillation, while thrombolysis is useful but limited by complication risks in acute scenarios.
Why the study?
AF is a common arrhythmia linked to thromboembolic complications such as stroke, warranting a review of its epidemiology, pathophysiology, and therapeutic strategies.
What are the therapeutic approaches and strategies to prevent thromboembolic events in patients with atrial fibrillation?
What are the therapeutic approaches and strategies to prevent thromboembolic events in patients with atrial fibrillation?
This review reinforces that DOACs are effective for stroke prevention in atrial fibrillation, while thrombolysis has a limited role in acute scenarios due to bleeding risks, emphasizing the need for personalized management.
Answers are grounded in this paper and cite their sources.
DOACs support thromboembolic prevention in AF; leaves open optimal integration of personalized and technological strategies.
Atrial fibrillation (AF) is a common arrhythmia linked to thromboembolic complications, such stroke.This study reviewed its epidemiology, pathophysiology, and therapeutic strategies, emphasizing the use of anticoagulants and thrombolysis.DOACs were shown to be effective for preventing thromboembolic events, while thrombolysis proved useful but limited in acute scenarios.The study concludes that technological advances and personalized approaches are crucial for improving AF management.
No takes yet. Share an insight, caveat, or question.
Andrade et al. (2025) conducted a review in Atrial fibrillation. Anticoagulants and thrombolysis was evaluated. Direct oral anticoagulants effectively prevent thromboembolic events in atrial fibrillation, while thrombolysis is useful but limited by complication risks in acute scenarios.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: